BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/16/2019 12:17:24 PM | Browse: 773 | Download: 1015
 |
Received |
|
2019-04-29 01:02 |
|
Peer-Review Started |
|
2019-05-09 03:09 |
|
To Make the First Decision |
|
2019-06-05 06:11 |
|
Return for Revision |
|
2019-06-17 03:35 |
|
Revised |
|
2019-07-25 15:19 |
|
Second Decision |
|
2019-08-23 09:30 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2019-08-28 01:18 |
|
Articles in Press |
|
2019-08-28 01:18 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2019-09-11 19:56 |
|
Typeset the Manuscript |
|
2019-10-14 09:34 |
|
Publish the Manuscript Online |
|
2019-10-16 12:17 |
| ISSN |
1948-5204 (online) |
| Open Access |
This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Review |
| Article Title |
Targeted agents for second-line treatment of advanced hepatocellular carcinoma
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Nicola Personeni, Tiziana Pressiani, Silvia Bozzarelli and Lorenza Rimassa |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Lorenza Rimassa, MD, Adjunct Professor, Chief Doctor, Humanitas Cancer Center, Humanitas Clinical and Research Center, IRCCS, via Manzoni 56, Rozzano 20089, Milan, Italy. lorenza.rimassa@cancercenter.humanitas.it |
| Key Words |
Hepatocellular carcinoma; Advanced-metastatic; Second-line; Third-line; Regorafenib; Cabozantinib |
| Core Tip |
During the last decade, sorafenib, a multikinase inhibitor, has emerged as the only systemic agent available for the treatment of patients with unresectable hepatocellular carcinoma. However, in recent years, lenvatinib, which is a different multikinase inhibitor, was shown to be non-inferior compared to sorafenib. Despite several negative phase III trials, novel drugs with similar, but not overlapping, properties have been recently shown to improve patient outcomes, thereby confirming the role of a sustained anti-angiogenic inhibition in further lines of treatment. Here, we will discuss the results of the positive phase III trials of regorafenib, cabozantinib, and ramucirumab in patients failing sorafenib. |
| Publish Date |
2019-10-16 12:17 |
| Citation |
Personeni N, Pressiani T, Bozzarelli S, Rimassa L. Targeted agents for second-line treatment of advanced hepatocellular carcinoma. World J Gastrointest Oncol 2019; 11(10): 788-803 |
| URL |
https://www.wjgnet.com/1948-5204/full/v11/i10/788.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v11.i10.788 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
